Trial Profile
A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs M 3541 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono Research & Development Institute
- 09 Feb 2023 Status changed to discontinued.
- 12 Feb 2022 Results of safety, pharmacokinetics and antitumor activity of M3541 in combination with palliative radiotherapy, published in the Investigational New Drugs
- 10 Sep 2020 Status changed from active, no longer recruiting to completed.